E
ALBO

Ergoteles’s Albireo Pharma Inc ALBO Stock Holding History

Ergoteles’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-19,943
Closed -$386K – 2086
2022
Q3 		$386K Buy
+19,943
New +$412K 0.01% 868
2022
Q2 		– Sell
-8,288
Closed -$247K – 2120
2022
Q1 		$247K Buy
+8,288
New +$243K 0.01% 909

Other funds holding ALBO

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Ergoteles's ALBO Position: Q4 2022 in Review

Ergoteles sold out of Albireo Pharma Inc (ALBO) in Q4 2022, closing a stake of 19,943 shares — an estimated $386K sold.

Ergoteles first reported a position in ALBO in Q1 2022 and held it in 2 quarters. The position peaked at $386K in Q3 2022. 96 funds tracked by Wall St. Rank hold ALBO as of Q4 2022.

  • Ergoteles reported no remaining Albireo Pharma Inc position as of Q4 2022 after selling out during the quarter.
  • Ergoteles sold 19,943 Albireo Pharma Inc shares in Q4 2022, an estimated $386K.
  • Ergoteles first reported a position in Albireo Pharma Inc in Q1 2022 and held it in 2 quarters.
  • Ergoteles's Albireo Pharma Inc position peaked at $386K in Q3 2022.
  • 96 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.